OPA1 and metabolic dysfunction-associated steatohepatitis: On the other hand, OPA1 depletion in the mouse liver was shown to rather decrease the non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) pathologies26,27.